Glycogen Storage Disease Type IV (Andersen Disease)
A rare disorder of glycogen branching enzyme deficiency that leads to abnormal glycogen accumulation, most often causing progressive liver disease or neuromuscular involvement.
- Autosomal Recessive
- GBE1 Gene Deficiency
- Variable Liver and Muscle Forms
- Most Common In
- Infancy through adulthood (variable forms)
- Inheritance
- Autosomal Recessive
- Key Gene
- GBE1
- Primary Management
- Supportive Care / Transplant
Condition Overview
Glycogen Storage Disease Type IV (Andersen disease) is caused by deficiency of the glycogen branching enzyme, encoded by the GBE1 gene. This enzyme deficiency results in the accumulation of abnormally structured, poorly branched glycogen (polyglucosan) within the liver, skeletal muscle, heart, and nervous system.
GSD IV is clinically heterogeneous. The classic hepatic form presents in infancy with progressive liver disease and cirrhosis, while neuromuscular forms can present at any age, ranging from severe perinatal or congenital presentations to milder adult-onset myopathy.
Types and Subtypes
GSD IV presents across a wide clinical spectrum.
Symptoms and Signs
Symptoms vary widely depending on the clinical subtype.
Causes and Risk Factors
GSD IV is caused by inherited mutations in the GBE1 gene.
Diagnosis and Investigations
Diagnosis combines clinical findings, enzyme assay, and genetic confirmation.
Disease Severity Classification
GSD IV severity is described by organ involvement and rate of progression rather than formal staging.
Standard Treatment
Treatment is largely supportive and tailored to the predominant organ involvement.
Advanced & Emerging Therapies
Treatment options beyond supportive care remain limited but are an active area of research.
Transplantation
Liver Transplantation
Established treatment for progressive liver failure in the classic hepatic form, with generally favorable outcomes when performed before severe extrahepatic disease develops.
Gene Therapy
Investigational GBE1 Gene Therapy Research
Early-stage research is exploring gene therapy approaches to restore branching enzyme activity.
Biomarkers & Monitoring Parameters
Several markers help guide ongoing management of GSD IV.
When to Seek a Second Opinion
Specialist input is particularly valuable in GSD IV given its variable presentation.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis in GSD IV varies dramatically depending on the clinical subtype.
Supportive Care
Supportive care is central to managing GSD IV given the limited disease-modifying treatment options.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families affected by GSD Type IV access hepatology, cardiology, and metabolic genetics specialists, review genetic and imaging reports, and explore transplant evaluation and research options.
Get a free case reviewFrequently Asked Questions
GSD Type IV (Andersen disease) is caused by deficiency of the glycogen branching enzyme, leading to abnormal glycogen accumulation that most often affects the liver but can also involve muscle, heart, and nervous system.
It is caused by inherited biallelic mutations in the GBE1 gene, passed down in an autosomal recessive pattern.
The classic hepatic form causes progressive liver disease in infancy, while neuromuscular forms range from severe congenital presentations to milder adult-onset muscle weakness.
Diagnosis involves liver function testing, imaging, and confirmatory GBE1 gene sequencing, sometimes supported by liver or muscle biopsy.
There is no cure, but liver transplantation can be effective for progressive liver failure in the classic hepatic form, and supportive care helps manage neuromuscular forms.
The outlook varies widely by subtype, ranging from severe disease in infancy to slowly progressive adult forms, so prognosis must be individualized.
Yes, adult polyglucosan body disease is a milder, later-presenting form of GSD IV that can affect peripheral nerves, the central nervous system, and muscle.
Yes. CancerFax can review your medical reports and genetic test results, help coordinate second opinions with metabolic disease specialists, and assist in exploring enzyme replacement therapy, gene therapy trials, or transplant evaluation at centers in India, China, and internationally.